<DOC>
	<DOCNO>NCT00345878</DOCNO>
	<brief_summary>Human papillomavirus infection clearly recognize cause cervical cancer . The infection cervix certain oncogenic type HPV , clear , lead cervical cancer woman . This study evaluate immunogenicity safety HPV-16/18 L1 VLP AS04 vaccine . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Study Evaluate Immune Response Safety GSK Biologicals ' HPV Vaccine Healthy Women Aged 18-35 Years</brief_title>
	<detailed_description>The protocol primarily amend follow reason : - Merck 's tetravalent HPV vaccine , GardasilÂ® , license become commercially available increase number country . Therefore , study procedure revise include question every visit determine subject receive HPV vaccine outside study . - It decide offer GSK Biologicals ' HPV vaccine subject control group end study . The HPV vaccine offer subject base local indication vaccine market Malaysia .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . A female Malaysia , include , 18 35 year age time first vaccination . Written inform consent obtain subject . Healthy subject establish medical history clinical examination enter study . Subjects must negative urine pregnancy test . Subjects childbearing potential time study entry must abstinent must use effective method birth control 30 day prior vaccination must agree continue precaution two month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol within 30 day 30 day first dose vaccine . Administration routine vaccine 8 day first dose study vaccine allow . Enrolment defer subject outside specify window . previous administration component investigational vaccine Previous vaccination HPV plan administration HPV vaccine foreseen study protocol study period . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History allergic disease reaction likely exacerbate component vaccine ( ) . Hypersensitivity latex . Acute disease time enrolment . Known acute chronic , clinically significant neurologic , pulmonary , cardiovascular , hepatic renal functional abnormality , determine previous physical examination laboratory test . History chronic condition ( ) require treatment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine ( ) plan administration study period . Enrolment defer subject outside specify window . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HPV-16/18 L1 VLP AS04</keyword>
	<keyword>Cervical neoplasia</keyword>
	<keyword>Cervical cancer</keyword>
	<keyword>Human Papillomavirus ( HPV )</keyword>
	<keyword>Double-blind</keyword>
	<keyword>AS04</keyword>
</DOC>